The status of growth hormone (GH) secretion together with the effect of GH therapy was studied in six children with achondroplasia. One patient had impaired GH secretion, which may, in part, be due to obesity. The pre-GH-treatment height velocity was 3.8 \m=+-\0.7cm/year, but this increased to 6.0\m=+-\1.0 cm/year in the first year of treatment and to 4.4\m=+-\0.6cm/year in the second year. One patient who underwent GH therapy for 4 years showed good response in height velocity. A considerable variation was observed in response to GH therapy within the treated cases.
Patients and methods Three boys and three girls with typical features of achondroplasia were studied. All patients were prepubertal before GH therapy. The 
Discussion
In this study, one patient with obesity and normal birth had impaired GH secretion, which may, in part, be due to chronic somatostatin, which is the inhibitory factor of GH secretion, hypersécrétion and/or reduced pituitary GH pool in obesity (7, 8) . Obesity is a common problem in achondroplasia (9) . Moreover, obstructive sleep apnea, which occurs in achondroplasia, impairs sleep-related GH secretion (10) , although none of our six patients had obstructive sleep apnea. There are several reports on GH therapy in achon¬ droplasia or hypochondroplasia (Table 2 ) (5, 11-16) but no reports on the effect of long-term GH treatment on final height. The efficacy of short-term GH therapy was reported in some children with achondroplasia or hypo¬ chondroplasia (5, (11) (12) (13) (14) (15) (16) ). An initial acceleration of growth was seen, but thereafter the growth waned. In this study, height velocity was accelerated during the 1st year of GH treatment but declined progressively during the subsequent years in achondroplasia; the magnitude of this height velocity was similar to that in hypochon¬ droplasia (15) , in Turner's syndrome (17) , in GHinsufficient children (18) and in normal short children (19) . Decreased 
